Effect of IFN-γ on Innate Immune Cells

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

August 31, 2018

Study Completion Date

February 28, 2019

Conditions
Chronic Granulomatous Disease
Interventions
DRUG

Administration of drug (Interferon-gamma 1-b) subcutaneously

SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.

Trial Locations (1)

80045

University of Colorado Denver, Anschutz Medical Campus, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT02609932 - Effect of IFN-γ on Innate Immune Cells | Biotech Hunter | Biotech Hunter